Karyopharm Therapeutics Inc (KPTI)

Karyopharm Therapeutics Inc (KPTI) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $8.8M; returns 1 day -5.2%, 1 week +32.7%, 1 year -91.6%.

Karyopharm Therapeutics Inc. (KPTI) is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel cancer therapies. Its core business revolves around pioneering oral compounds that target nuclear export dysregulation, a key mechanism in oncogenesis, through its proprietary Selective Inhibitor of Nuclear Export (SINE) compounds.

Groups KPTI belongs to

• Healthcare
• Biotechnology
• Pharmaceuticals
• Oncology
• Cancer Therapeutics
• Commercial Stage Biotech
• Commercial Stage
• Biopharmaceutical
• Life Sciences
• Hematologic Malignancies
• Hematology
• Drug Discovery

KPTI financial model: income statement, cash flow and balance sheet